Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932280 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
A Phase 1 study of Lymphoma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 9
- Study locations
NCT02932280 is a Phase 1 study of Lymphoma and Leukemia that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 14 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT02932280, a Phase 1 study of Lymphoma and Leukemia, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
Conditions Studied
Interventions
- DRUG Neratinib
Study Locations (9)
Arizona
- Phoenix Children'S Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- Stanford University School of Medicine and Stanford Cancer Institute - Palo Alto
Florida
- Arnold Palmer Hospital for Children - Orlando
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Pennsylvania State Hershey Children's Hospital - Hershey
Texas
- University of Texas - San Antonio
Utah
- Huntsman Cancer Institue - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-10 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02932280
The ClinicalTrials.gov registry entry for NCT02932280 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (97% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Neratinib is the first listed.
NCT02932280 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT02932280 about?
NCT02932280 is a clinical study titled "Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment". The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
What is the current status of trial NCT02932280?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-10. Estimated completion is 2026-10.
What conditions does trial NCT02932280 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Solid Tumor, Central Nervous System Tumor.
What interventions are being tested in trial NCT02932280?
The interventions under investigation include: Neratinib (DRUG).
Who is sponsoring clinical trial NCT02932280?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02932280 being conducted?
This trial has 9 study locations across Arizona, Arkansas, California, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.